

REMARKS

I. Introduction

This application is a continuation of pending application serial number 10/199,222, filed July 18, 2002, which is a continuation of application serial number 09/550,371, filed April 14, 2000, now U.S. patent no. 6,464,986 B1.

The title of this application has been replaced by a title more descriptive of the claimed subject matter and a cross reference to the parent applications has been added after the title.

Applicants hereby cancel claims 22-23 without prejudice to further prosecution at a later date.

The amendment to claim 1 ("joint pain") is supported by at least page 30, line 1, and by Example 7 on pages 44, lines 12-19 of the application.

The amendment to claim 12 ("joint pain" and "botulinum toxin type A") is supported by at least page 30, line 1, by Example 7 on page 44, lines 12-19 of the application, and by original claim 5.

New claim 28 ("peripheral administration") is supported by at least original claim 1.

New claim 29 ("intramuscular administration") is supported by at least page 30, lines 1-2 of the specification.

New claim 30 ("into the region of the painful joint") is supported by at least Example 7 on page 44 of the specification.

New claim 31 ("not associated with a muscle spasm") is supported by at least original claim 1 and by Example 7 on page 44 of the specification.

New claim 32 ("arthritis pain") is supported by at least Example 2 on page 42 of the specification and by Example 7 on page 44 of the specification.

New claim 33 ("method for treating arthritis") is supported by at least Example 2 on page 42 of the specification and by Example 7 on page 44 of the specification.

New claim 34 ("botulinum toxin type A) is supported by at least original claim 5.


No new matter is added by any of these claim amendments.

II. Conclusion

Examination and allowance of claims 1, 4-5, 9, 12-13 and 28-34 is requested.

Respectfully Submitted,

Date: July 29, 2003


Stephen Donovan
Registration Number 33,433


Please direct all correspondence and inquiries to:

Stephen Donovan
Allergan, Inc.
2525 Dupont Drive
Irvine, California 92612
Telephone: 714 246 4026
Fax: 714 246 4249

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this Preliminary Amendment and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date July 29, 2003 in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV2956830120US addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew
Name of person mailing paper


Signature of person mailing paper

Date: July 29, 2003